Avalyn Pharma (AVLN) vs Immatics N.V. (IMTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.14 billion vs $1.12 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | IMTX |
|---|---|---|
| Share price | $25.72 | $7.37 |
| Market cap | $1.14B | $1.12B |
| 1-day change | +0.74% | -1.07% |
| YTD return | — | -29.05% |
| 1-year return | — | -20.83% |
| 5-year return | — | -46.21% |
| EPS (TTM) | $-2.47 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.17 | $12.41 |
| 52-week low | $24.15 | $7.02 |
| Distance from 52-week high | -35.97% | -40.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +140.28% | +139.21% |
| Average volume | 234.81K | 595.07K |
| Shares outstanding | 44.33M | 152.23M |
| Employees | 55 | 704 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
AVLN vs IMTX FAQ
Which is bigger, Avalyn Pharma or Immatics N.V.?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.14B compared with $1.12B for Immatics N.V. (IMTX).
Are Avalyn Pharma and Immatics N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Avalyn Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for Immatics N.V..